Socialised Medicine: Life-Prolonging Drug Deemed ‘Too Expensive’ for NHS Breast Cancer Patients
Breast cancer patients in England will not be able to avail themselves of a life-prolonging drug after the country’s socialised healthcare system deemed it “too expensive”.
A drug that would prolong the lives of those with advanced breast cancer will not be made available to many patients in England after the country’s socialised healthcare system ruled it to be “too expensive”.
While the medicine known as Trodelvy will be made available publicly in Scotland, which manages its own state healthcare system, England’s National Institute for Health and Care Excellence (NICE) has decided it would be best that women south of the border not be able to avail themselves of the drug, claiming that it is not “cost-effective use of [National Health Service] resources”.
According to a report by The Telegraph, around 650 women in England would have benefitted from taking the drug, with one charity describing the decision as a “devastating blow”.- READ MORE
Responses